{"id":24111,"date":"2024-06-01T07:19:57","date_gmt":"2024-06-01T11:19:57","guid":{"rendered":"https:\/\/massivebio.com\/?p=20468"},"modified":"2025-09-25T13:24:06","modified_gmt":"2025-09-25T10:24:06","slug":"massivebio-to-unveil-drug-utilization-optimizer-duo","status":"publish","type":"post","link":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/","title":{"rendered":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024"},"content":{"rendered":"<\/p>\r\n

Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024<\/strong><\/p>\r\n\r\n

<\/p>\r\n

June 1st<\/sup> 2024, ASCO Annual Meeting, Chicago \u2013 <\/strong>Massive Bio<\/a><\/u><\/span>, pioneering leader in AI-driven oncology solutions, is excited to announce the launch of its latest product, Drug Utilization Optimizer (DUO), at the upcoming ASCO Annual Meeting 2024. The innovative analytics and real-time notification platform is designed to revolutionize how pharmaceutical commercial teams target and engage with physicians, providing unparalleled insights and efficiency.<\/p>\r\n

<\/p>\r\n

Building on the success of the SYNERGY-AI platform, which excels in anonymizing data, structuring documents, and matching patients to over 14,000 cancer clinical trials in real time, DUO extends Massive Bio’s capabilities into the commercial realm. DUO is specifically aimed at identifying potential opportunities for pharma commercial teams to analyze the competitive landscape far beyond outdated claims-based data, leveraging Massive Bio’s advanced analytics and data platform.<\/p>\r\n

<\/p>\r\n

“Our new DUO platform is a game-changer for pharmaceutical commercial teams,” said Selin Kurnaz, PhD<\/a><\/u><\/span>, Co-Founder and CEO of Massive Bio. “By providing real-time, granular insights, DUO empowers teams to connect with the right physicians and surface relevant patients with unmatched efficiency, driving brand revenues and reducing sales costs. Pharmaceutical companies have been working with claims and de-identified data for a long time and understanding real time patient journeys has been long over-due to provide the most responsive access to drugs. Most importantly, when a patient is under-genotyped, we support the patient to get tested which means that we don\u2019t see patients as data points on a map, we operationalize the data so that patients get access to the enablers (such as molecular diagnostics testing) to get access to the drug. That is one of the reasons why we are miles different than traditional real world data companies”.<\/p>\r\n\r\n

Key Features and Value Proposition of DUO:<\/h2>\r\n

<\/p>\r\n

\u2022 AI-Enabled Oncology\/Hematology Platform: <\/strong>Designed for physician targeting with real-time insights, DUO helps commercial teams identify key physicians and influence behavior at local, regional, and country levels through a seamless platform.<\/p>\r\n

<\/p>\r\n

\u2022 Boost Brand Revenues & Cut Sales Costs:<\/strong> DUO enhances brand revenues by 5-10% and reduces sales force costs by 10-15% annually through superior physician targeting. For new, competitive, and rare disease products, DUO delivers double the value.<\/p>\r\n

<\/p>\r\n

\u2022 Unmatched & Growing Patient Insights: <\/strong>With over 120,000 cancer patients on board and 5-7k new patients added each month, DUO offers deep clinical and genomic data for precision physician targeting, surpassing traditional real-world data sources reliant on claims or EMR data.<\/p>\r\n

<\/p>\r\n

\u2022 Identify Key Physicians & Influence Behavior:<\/strong> DUO identifies physicians conducting Next Generation Sequencing (NGS) or other diagnostics, surfacing these key influencers to pharma. It also facilitates testing for patients in need, changing physician behavior and delivering unparalleled value beyond traditional real-world data companies.<\/p>\r\n

<\/p>\r\n

\u2022 Global Oncology Expertise: <\/strong>As a global oncology and hematology company, Massive Bio blends clinical expertise with technical prowess, offering a network of 4,600+ physicians and unmatched data access.<\/p>\r\n

<\/p>\r\n

“DUO is not just a tool; it’s a transformative solution for pharmaceutical commercial teams,” said Dr. Arturo Loaiza-Bonilla, MD MSEd,<\/a><\/u><\/span> Co-Founder and Chief Medical Officer of Massive Bio. “By harnessing the power of AI and real-time data, we are setting a new standard in physician targeting and patient engagement.”<\/p>\r\n

<\/p>\r\n

We invite all stakeholders, especially pharmaceutical company commercial teams, brand teams, and physician targeting teams, to visit our booth (#29137) at ASCO 2024 for a demo of DUO. Discover how DUO can drive your commercial success in oncology and hematology.<\/p>\r\n

<\/p>\r\n

For more information and to schedule a demo, please visit: <\/strong>
https:\/\/www.massivebio.com\/clinical-network\/<\/a><\/u><\/span><\/p>\r\n

<\/p>\r\n[\/vc_column_text][\/vc_column][\/vc_row]

<\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div><\/div><\/div><\/div><\/div><\/div><\/section>

<\/p>\n

Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024<\/strong><\/p>\n

<\/p>\n

<\/p>\n

June 1st<\/sup> 2024, ASCO Annual Meeting, Chicago \u2013 <\/strong>Massive Bio<\/a><\/u><\/span>, pioneering leader in AI-driven oncology solutions, is excited to announce the launch of its latest product, Drug Utilization Optimizer (DUO), at the upcoming ASCO Annual Meeting 2024. The innovative analytics and real-time notification platform is designed to revolutionize how pharmaceutical commercial teams target and engage with physicians, providing unparalleled insights and efficiency.<\/p>\n

<\/p>\n

Building on the success of the SYNERGY-AI platform, which excels in anonymizing data, structuring documents, and matching patients to over 14,000 cancer clinical trials in real time, DUO extends Massive Bio’s capabilities into the commercial realm. DUO is specifically aimed at identifying potential opportunities for pharma commercial teams to analyze the competitive landscape far beyond outdated claims-based data, leveraging Massive Bio’s advanced analytics and data platform.<\/p>\n

<\/p>\n

“Our new DUO platform is a game-changer for pharmaceutical commercial teams,” said Selin Kurnaz, PhD<\/a><\/u><\/span>, Co-Founder and CEO of Massive Bio. “By providing real-time, granular insights, DUO empowers teams to connect with the right physicians and surface relevant patients with unmatched efficiency, driving brand revenues and reducing sales costs. Pharmaceutical companies have been working with claims and de-identified data for a long time and understanding real time patient journeys has been long over-due to provide the most responsive access to drugs. Most importantly, when a patient is under-genotyped, we support the patient to get tested which means that we don\u2019t see patients as data points on a map, we operationalize the data so that patients get access to the enablers (such as molecular diagnostics testing) to get access to the drug. That is one of the reasons why we are miles different than traditional real world data companies”.<\/p>\n

<\/p>\n

Key Features and Value Proposition of DUO:<\/h2>\n

<\/p>\n

\u2022 AI-Enabled Oncology\/Hematology Platform: <\/strong>Designed for physician targeting with real-time insights, DUO helps commercial teams identify key physicians and influence behavior at local, regional, and country levels through a seamless platform.<\/p>\n

<\/p>\n

\u2022 Boost Brand Revenues & Cut Sales Costs:<\/strong> DUO enhances brand revenues by 5-10% and reduces sales force costs by 10-15% annually through superior physician targeting. For new, competitive, and rare disease products, DUO delivers double the value.<\/p>\n

<\/p>\n

\u2022 Unmatched & Growing Patient Insights: <\/strong>With over 120,000 cancer patients on board and 5-7k new patients added each month, DUO offers deep clinical and genomic data for precision physician targeting, surpassing traditional real-world data sources reliant on claims or EMR data.<\/p>\n

<\/p>\n

\u2022 Identify Key Physicians & Influence Behavior:<\/strong> DUO identifies physicians conducting Next Generation Sequencing (NGS) or other diagnostics, surfacing these key influencers to pharma. It also facilitates testing for patients in need, changing physician behavior and delivering unparalleled value beyond traditional real-world data companies.<\/p>\n

<\/p>\n

\u2022 Global Oncology Expertise: <\/strong>As a global oncology and hematology company, Massive Bio blends clinical expertise with technical prowess, offering a network of 4,600+ physicians and unmatched data access.<\/p>\n

<\/p>\n

“DUO is not just a tool; it’s a transformative solution for pharmaceutical commercial teams,” said Dr. Arturo Loaiza-Bonilla, MD MSEd,<\/a><\/u><\/span> Co-Founder and Chief Medical Officer of Massive Bio. “By harnessing the power of AI and real-time data, we are setting a new standard in physician targeting and patient engagement.”<\/p>\n

<\/p>\n

We invite all stakeholders, especially pharmaceutical company commercial teams, brand teams, and physician targeting teams, to visit our booth (#29137) at ASCO 2024 for a demo of DUO. Discover how DUO can drive your commercial success in oncology and hematology.<\/p>\n

<\/p>\n

For more information and to schedule a demo, please visit: <\/strong>
https:\/\/www.massivebio.com\/clinical-network\/<\/a><\/u><\/span><\/p>\n

<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/section>

<\/div><\/div><\/div><\/div><\/div><\/div><\/section>","protected":false},"excerpt":{"rendered":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024 June 1st 2024, ASCO Annual Meeting, Chicago \u2013 Massive Bio, pioneering leader in AI-driven oncology solutions, is excited to announce the launch of its latest product, Drug Utilization Optimizer (DUO), at the upcoming ASCO Annual Meeting 2024. The innovative analytics and real-time...","protected":false},"author":11,"featured_media":23955,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-24111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"\nMassive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024<\/title>\n<meta name=\"description\" content=\"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024 %\" \/>\n<meta property=\"og:description\" content=\"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024\" \/>\n<meta property=\"og:url\" content=\"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/\" \/>\n<meta property=\"og:site_name\" content=\"Massive Bio\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-01T11:19:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-25T10:24:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/06\/DUO-announcement-mobil.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"576\" \/>\n\t<meta property=\"og:image:height\" content=\"432\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sinan Gul\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:site\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sinan Gul\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024","description":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/","og_locale":"en_US","og_type":"article","og_title":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024 %","og_description":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024","og_url":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/","og_site_name":"Massive Bio","article_publisher":"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","article_published_time":"2024-06-01T11:19:57+00:00","article_modified_time":"2025-09-25T10:24:06+00:00","og_image":[{"width":576,"height":432,"url":"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/06\/DUO-announcement-mobil.webp","type":"image\/webp"}],"author":"Sinan Gul","twitter_card":"summary_large_image","twitter_creator":"@MassiveBio","twitter_site":"@MassiveBio","twitter_misc":{"Written by":"Sinan Gul","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/#article","isPartOf":{"@id":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/"},"author":{"name":"Sinan Gul","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6"},"headline":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024","datePublished":"2024-06-01T11:19:57+00:00","dateModified":"2025-09-25T10:24:06+00:00","mainEntityOfPage":{"@id":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/"},"wordCount":630,"publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"image":{"@id":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/06\/DUO-announcement-mobil.webp","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/","url":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/","name":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024","isPartOf":{"@id":"https:\/\/massivebio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/#primaryimage"},"image":{"@id":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/06\/DUO-announcement-mobil.webp","datePublished":"2024-06-01T11:19:57+00:00","dateModified":"2025-09-25T10:24:06+00:00","description":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024","breadcrumb":{"@id":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/#primaryimage","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/06\/DUO-announcement-mobil.webp","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2024\/06\/DUO-announcement-mobil.webp","width":576,"height":432,"caption":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024"},{"@type":"BreadcrumbList","@id":"https:\/\/massivebio.com\/massivebio-to-unveil-drug-utilization-optimizer-duo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/massivebio.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/massivebio.com\/resources\/news-en\/"},{"@type":"ListItem","position":3,"name":"Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024"}]},{"@type":"WebSite","@id":"https:\/\/massivebio.com\/#website","url":"https:\/\/massivebio.com\/","name":"Cancer Analysis and Clinical Trial Matching","description":"Best Oncology Advisory Services By Cancer Treatment Care Specialists & Tumor Board Experts in America","publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/massivebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/massivebio.com\/#organization","name":"Massive Bio","url":"https:\/\/massivebio.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","width":"1024","height":"1024","caption":"Massive Bio"},"image":{"@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","https:\/\/x.com\/MassiveBio","https:\/\/instagram.com\/massive_bio\/","https:\/\/tiktok.com\/@massivebio","https:\/\/youtube.com\/massivebio"],"email":"support@massivebio.com","legalName":"Massive Bio"},{"@type":"Person","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6","name":"Sinan Gul"}]}},"_links":{"self":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/24111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/comments?post=24111"}],"version-history":[{"count":5,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/24111\/revisions"}],"predecessor-version":[{"id":37792,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/24111\/revisions\/37792"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media\/23955"}],"wp:attachment":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media?parent=24111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/categories?post=24111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/tags?post=24111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}